Información del artículo
Resumen
Como cada año en el congreso de la Asociación Gastroenterológica Americana (Digestive Diseases Week [DDW]), se han presentado muchísimos trabajos, unos mejores y otros no tan buenos, de los que hemos intentado hacer una labor de discriminación y de síntesis. En términos generales, podemos decir que se consolidan ciertos avances tecnológicos, con incorporación plena a la práctica clínica, como la impedanciometría y la manometría de alta resolución. Surgen nuevos datos fisiopatológicos que apuntan aún más a la unificación y conexión inexorable de los aspectos orgánicos y psicológicos (modelo biopsicosocial) en los trastornos funcionales digestivos (TFD).
Se pusieron muchas esperanzas en los criterios de Roma III para mejorar el diagnóstico de los TFD y, en especial, de la dispepsia funcional. Sin embargo, su aplicación práctica ha sido bastante desalentadora. Además, al menos 2 estudios han comprobando que dichos criterios son poco discriminativos para diferenciar los subtipos de DF y que existe mucho solapamiento con la enfermedad por reflujo gastroesofágico.
Respecto a los 2 principales TFD, la dispepsia funcional y el síndrome del intestino irritable (SII), se presentaron nuevos datos sobre la importancia de los factores genéticos, microinflamatorios o psicológicos en la etiopatogenia de ambos trastornos. Desde el punto de vista terapéutico se presentaron resultados de la eficacia y seguridad de acotiamida en la dispepsia funcional, y de linaclotida y prucaloprida en el estreñimiento, tanto idiopático como asociado al SII.
Diversos estudios, e incluso metaanálisis, han demostrado la utilidad del biofeedback en el tratamiento del estreñimiento. Aun así, su eficacia se ha puesto en duda debido a ciertas deficiencias metodológicas de algunas investigaciones. En este DDW se presentaron trabajos que confirman la utilidad del biofeedback, ya sea hospitalario o domiciliario, en el estreñimiento por disinergia.
Se recogen también algunos aspectos de especial interés en el diagnóstico y tratamiento del síndrome de rumiación, del dolor torácico de posible origen esofágico y del síndrome de hiperemesis por canabinoides.
Palabras clave:
Acalasia
Dispepsia funcional
Estreñimiento funcional
Linaclotida
Motilidad digestiva
Incontinencia
Síndrome del intestino irritable
Trastornos funcionales digestivos
Prucaloprida
Abstract
As in previous years, a huge number of studies were presented at the Congress of the American Gastroenterology Association (Digestive Diseases Week [DDW]), some of which were better than others. The present article attempts to extract and summarize the most interesting findings reported. In general terms, certain technological advances have been consolidated, with full incorporation into clinical practice, such as impedancemetry and high-resolution manometry. New physiopathological data are coming to light that increasingly indicate the inextricable link between organic and psychological factors (the biopsychosocial model) in functional gastrointestinal disorders (FGID).
Despite the high hopes that the Rome III criteria would improve the diagnosis of FGID and especially that of functional dyspepsia, their practical application has been fairly discouraging. Moreover, at least two studies have demonstrated that these criteria cannot be used to differentiate subtypes of functional dyspepsia and that there is wide overlap with gastroesophageal reflux disease.
New data were presented on the role of genetic, microinflammatory and psychological factors in the etiopathogenesis of the two main FGID: functional dyspepsia and irritable bowel syndrome (IBS). The results on the safety and efficacy of acotiamide in functional dyspepsia and of linaclotide and prucalopride in idiopathic and IBS-associated constipation were also presented.
Several studies, and even meta-analyses, have demonstrated the utility of biofeedback in the treatment of constipation. Even so, the efficacy of this therapy has been questioned due to certain methodological deficiencies in some studies. In DDW 2011, studies confirming the utility of biofeedback, whether hospital- or home-based were presented, in dyssynergy constipation.
The present article also mentions certain features of special interest in the diagnosis and treatment of rumination syndrome, thoracic pain of possible esophageal origin and cannabinoid-induced hyperemesis syndrome.
Keywords:
Achalasia
Functional dyspepsia
Functional constipation
Linaclotide
Gastrointestinal motility
Incontinence
Irritable bowel syndrome
Functional gastrointestinal disorders
Prucalopride
El Texto completo está disponible en PDF
Bibliografía
[1.]
J. Tack, N.J. Talley, M. Camilleri, et al.
Functional gastroduodenal disorders: a working team report for the Rome III consensus on functional gastrointestinal disorders.
Gastroenterology, 130 (2006), pp. 1466-1479
[2.]
N.B. Vakil, K. Halling, B. Wernersson, L. Ohlsson.
ROME III Functional Dyspepsia (FD) Criteria: poor discrimination between postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS).
Gastroenterology, 140 (2011), pp. S25-S26
[3.]
N.B. Vakil, K. Halling, B. Wernersson, L. Ohlsson.
ROME III Functional dyspepsia criteria: substantial symptom overlap with GERD questions their validity.
Gastroenterology, 140 (2011), pp. S188
[4.]
M. Pathikonda, S. Kantor, R.S. Fisher, L.C. Knight, A.H. Maurer, H.P. Parkman.
Regional analysis of gastric emptying scintigraphy provides better correlation of dyspeptic symptoms with abnormal gastric emptying.
Gastroenterology, 140 (2011), pp. S25
[5.]
T. Oshima, T. Yamasaki, T. Okugawa, et al.
Augmented symptomatic response to acid in patients with functional dyspepsia.
Gastroenterology, 140 (2011), pp. S188
[6.]
Y. Cao, X. Li, R.K. Wong, K.Y. Ho, C.H. Wilder-Smith.
Dysfunctional endogenous pain modulation (EPM) in patients with functional dyspepsia (FD) and its clinical relevance.
Gastroenterology, 140 (2011), pp. S707
[7.]
S.B. Pignataro, E.H. Campitelli, T. Barcia, et al.
Functional dyspepsia and duodenal eosinophilia: a case control study in a South American country.
Gastroenterology, 140 (2011), pp. S169
[8.]
H. Hanne Vanheel, T. Tim Vanuytsel, L. Lieselot Holvoet, et al.
A pilot study on duodenal mucosal integrity in functional dyspepsia.
Gastroenterology, 140 (2011), pp. S169
[9.]
L. Van Oudenhove, J. Vandenberghe, B. Geeraerts, et al.
Determinants of symptoms in functional dyspepsia: gastric sensorimotor function, psychosocial factors or somatisation?.
Gut, 57 (2008), pp. 1666-1673
[10.]
L. Van Oudenhove, M. Jones, R. Vos, L. Holvoet, J.F. Tack.
Associations between gastric sensorimotor function, depression, ‘somatization’ and symptom-based subgroups in functional gastroduodenal disorders: are all symptoms equal?.
Gastroenterology, 140 (2011), pp. S463
[11.]
J.F. Tack, V. Stanghellini, G. Holtmann, et al.
Efficacy and safety study of acotiamide (Z-338) in European patients with functional dyspepsia.
Gastroenterology, 140 (2011), pp. S805
[12.]
K. Matsueda, M. Hongo, J.F. Tack, Y. Saito, H. Kato.
Efficacy of acotiamide (Z-338) in patients with postprandial distress syndrome or overlap of epigastric pain syndrome and postprandial distress syndrome in functional dyspepsia.
Gastroenterology, 140 (2011), pp. S805
[13.]
K. Matsueda, M. Hongo, J.F. Tack, Y. Saito, H. Kato.
Acotiamide (Z-338) significantly improves health-related quality of life and subjects’ global assessment of overall treatment efficacy in patients with functional dyspepsia: results from a randomized, double-blind, placebo-controlled phase iii trial in japan.
Gastroenterology, 140 (2011), pp. S803
[14.]
K. Matsueda, M. Hongo, S. Ushijima, H. Akiho, H. Kato.
A Long-term study of acotiamide in patients with functional dyspepsia: results from an open-labeled phase III trial in Japan on safety and efficacy.
Gastroenterology, 140 (2011), pp. S805
[15.]
J.C. Wu, P.K. Cheong, Y. Chan, et al.
A randomized, double-blind, placebo-controlled trial of low dose imipramine for treatment of refractory functional dyspepsia (FD).
Gastroenterology, 140 (2011), pp. S50
[16.]
D. Cherian, H.P. Parkman.
Fatigue: an important symptom in patients with gastroparesis.
Gastroenterology, 140 (2011), pp. S803-S804
[17.]
W.L. Hasler, K.P. May, L. Wilson, et al.
Post-infectious gastroparesis: differences in baseline clinical characteristics and evolution of symptoms and disease severity after 48 weeks versus patients without infectious prodromes.
Gastroenterology, 140 (2011), pp. S707
[18.]
H.P. Parkman, M. Jacobs, M. Pathikonda, et al.
Clinical, demographic, and pharmacogenetic associations with the clinical response and side effects to metoclopramide.
Gastroenterology, 140 (2011), pp. S24
[19.]
R. Datta, C. Soulard, M. Teillot, et al.
RM-131: a potent gastroprokinetic agent.
Gastroenterology, 140 (2011), pp. S25
[20.]
R.S. Choung, J.Y. Chang, G.R. Locke, C.D. Schleck, A.R. Zinsmeister, N.J. Talley.
The natural history of functional gastrointestinal disorders over 20 years: a population based study.
Gastroenterology, 140 (2011), pp. S112
[21.]
R.S. Choung, J.Y. Chang, G.R. Locke, C.D. Schleck, A.R. Zinsmeister, N.J. Talley.
Is having multiple functional gastrointestinal disorders distinct from having a single FGID? A population based study.
Gastroenterology, 140 (2011), pp. S708
[22.]
M.A. Van Tilburg, O.S. Palsson, M. Kanazawa, M.J. Turner, W.E. Whitehead.
Excess co-morbidity in ibs: increased neural sensitivity or response bias?.
Gastroenterology, 140 (2011), pp. S93-S94
[23.]
F. Mongeau, A. Gougeon, M. Bouin, P. Poitras.
Long term evolution of extra gastrointestinal (GI) symptoms in patients with functional GI disorders (FGID).
Gastroenterology, 140 (2011), pp. S468
[24.]
C. Hammer, P. Becker, J. Sambel, et al.
SNP Analysis of genes involved in the serotonergic pathway in iBS.
Gastroenterology, 140 (2011), pp. S529
[25.]
S.N. Horst, D.A. Schwartz, D.B. Beaulieu, et al.
A pilot study of gene expression profiling to differentiate irritable bowel syndrome subjects from normal controls.
Gastroenterology, 140 (2011), pp. S534
[26.]
T. Chiba, S. Onodera, T. Sugai, W. Habano, K. Suzuki.
A Genetic association between beta-3-aderenoceptor and cholinergic receptor muscarinic 3 polymorphisms in irritable bowel syndrome.
Gastroenterology, 140 (2011), pp. S534-S535
[27.]
M.A. Van Tilburg, E.A. Zaki, R.G. Boles.
Mitochondrial inheritance in one-sixth of adults with irritable bowel syndrome.
Gastroenterology, 140 (2011), pp. S111-S112
[28.]
M. Camilleri, P. Carlson, S. McKinzie, et al.
Genetic susceptibility to inflammation is associated with colonic transit and other intermediate phenotypes in irritable bowel syndrome.
Gastroenterology, 140 (2011), pp. S152
[29.]
M.B. Bengtson, J.R. Harris, M.H. Vatn.
Co-Occurrence of IBS, depression and anxiety, among norwegian twins, is influenced by both heredity and intrauterine growth.
Gastroenterology, 140 (2011), pp. S89
[30.]
Q. Li, S.K. Sarna.
Developmental origins of irritable bowel syndrome (IBS)-like symptoms: epigenetic dysregulation.
Gastroenterology, 140 (2011), pp. S121
[31.]
S. Hong, G. Zheng, J.W. Wiley.
Chronic stress-induced visceral hyperalgesia: evidence for epigenetic regulation of DNA methyltransferase I (Dnmt1) in dorsal root ganglion (DRG) neurons innervating the colon in the rat.
Gastroenterology, 140 (2011), pp. S131
[32.]
M. Pyleris, E.J. Giamarellos-Bourboulis, B. Koussoulas, C. Barbatzas, M. Pimentel.
Small bowel culture confirms the presence of small intestinal bacterial overgrowth in a subset of IBS subjects.
Gastroenterology, 140 (2011), pp. S152
[33.]
C. Jacobs, A. Attaluri, J. Valestin, G.K. Zamba, S.S. Rao.
PPI Use, dysmotility and prior GI surgery are risk factors for small intestinal bacterial overgrowth (SIBO) and small intestinal fungal overgrowth (SIFO).
Gastroenterology, 140 (2011), pp. S708
[34.]
I.B. Jeffery, P.W. O’ Toole, L. Ohman, et al.
Pyrosequencing reveals irritable bowel syndrome subtype defined by speciesspecific alterations in the microbial gut environment.
Gastroenterology, 140 (2011), pp. S151
[35.]
C. Cremon, B. Balestra, G. Dothel, et al.
Colonic mucosal mediators from patients with irritable bowel syndrome excite guinea pig enteric cholinergic motor neurons via purinergic, prostaglandin, and TRPV1 pathways.
Gastroenterology, 140 (2011), pp. S129
[36.]
J. Overington, C.O. Ibeakanma, F. Ochoa-Cortes, N.W. Bunnett, F. Cattaruzza, S.J. Vanner.
Cysteine proteases in supernatants from colonic biopsies obtained from diarrhea-predominant IBS patients evoke sustained hyperexcitability of colonic dorsal root ganglia neurons.
Gastroenterology, 140 (2011), pp. S523-S524
[37.]
S. Buhner, Q. Li, B. Braak, et al.
Excitation of enteric neurons by supernatants of colonic biopsies from irritable bowel syndrome patients (IBS) is linked to visceral sensitivity.
Gastroenterology, 140 (2011), pp. S521
[38.]
S.J. Coen, M. Kano, V. Kumari, A.D. Farmer, S.C. Williams, Q. Aziz.
Neuroticism influences brain activity during the experience of visceral pain.
Gastroenterology, 140 (2011), pp. S57
[39.]
K. Tillisch, M.B. Larsson, L.A. Kilpatrick, et al.
Women with irritable bowel syndrome (IBS) show altered default mode network connectivity.
Gastroenterology, 140 (2011), pp. S364
[40.]
D. Cerjak, R. Babygirija, M. Bülbül, S. Yoshimoto, K.A. Ludwig, T. Takahashi.
Empathy attenuates stress responses of GI tract via upregulating hypothalamic oxytocin expression.
Gastroenterology, 140 (2011), pp. S93
[41.]
P. Desreumaux, C. Neut, M. Cazaubiel, P. Matthieu, P. Fanny, J. Peter.
Saccharomyces cerevisiae CNCM I-3856 reduces digestive discomfort and abdominal pain in subjects with irritable bowel syndrome: a randomized double-blinded placebo-controlled clinical trial.
Gastroenterology, 140 (2011), pp. S50
[42.]
A.Y. Thijssen, D. Jonkers, V. Vankerckhoven, et al.
A randomised, placebo controlled, double blind study to assess the efficacy of a probiotic dairy product containing lactobacillus casei shirota on symptoms in irritable bowel syndrome.
Gastroenterology, 140 (2011), pp. S609
[43.]
S.B. Menees, M. Maneerattanaporn, W.D. Chey.
Efficacy of rifaximin in patients with irritable bowel syndrome: a meta-analysis.
Gastroenterology, 140 (2011), pp. S49-S50
[44.]
W.D. Chey, M. Pimentel, D.S. Riff, et al.
Time to onset and durability of relief in non-constipation ibs patients over 12 weeks following a 2-week course of rifaximin.
Gastroenterology, 140 (2011), pp. S605
[45.]
W.D. Chey, A. Lembo, J.E. MacDougall, B.J. Lavins, H. Schneier, J.M. Johnston.
Efficacy and safety of once-daily linaclotide administered orally for 26 weeks in patients with IBS-C: results from a randomized, double-blind, placebo-controlled phase 3 trial.
Gastroenterology, 140 (2011), pp. S135
[46.]
S. Rao, A. Lembo, S.J. Shiff, K. Shi, J.M. Johnston, H. Schneier.
Efficacy and safety of once daily linaclotide in patients with irritable bowel syndrome with constipation: a 12-week, randomized randomized, double-blind, placebo-controlled phase 3 trial followed by a 4-week randomized withdrawal period.
Gastroenterology, 140 (2011), pp. S138
[47.]
R. Carson, S. Tourkodimitris, B.E. Lewis, J.M. Johnston.
Effect of linaclotide on quality of life in adults with irritable bowel syndrome with constipation: pooled results from two randomized, double-blind, placebo-controlled phase 3 trials.
Gastroenterology, 140 (2011), pp. S51
[48.]
A. Bajor, M. Rudling, K.A. Ung, J. Wallin, M. Simren.
Impact of bile acids on ibs symptoms and the effects of resin treatment.
Gastroenterology, 140 (2011), pp. S3
[49.]
B.S. Wong, M. Camilleri, P. Carlson, et al.
Pharmacogenetics of the effects of colesevelam on colonic transit in irritable bowel syndrome with diarrhea.
Gastroenterology, 140 (2011), pp. S524-S525
[50.]
B.S. Wong, M. Camilleri, I.A. Busciglio, L.A. Szarka, D.D. Burton, A.R. Zinsmeister.
Pharmacodynamic effects of dronabinol, a nonselective cannabinoid receptor agonist, on colonic sensory and motor functions in irritable bowel syndrome.
Gastroenterology, 140 (2011), pp. S2
[51.]
A.G. Spencer, J.W. Jacobs, M.R. Leadbetter, et al.
RDX5791, a first-in-class minimally systemic NHE3 inhibitor in clinical development for CIC and IBS-C, increases intestinal sodium leading to enhanced intestinal fluid volume and transit.
Gastroenterology, 140 (2011), pp. S99
[52.]
H. Eutamene, D. Charmot, M. Navre, L. Bueno.
Visceral antinociceptive effects of RDX5791, a first-in-class minimally systemic NHE3 inhibitor on stress-induced colorectal hypersensitivity to distension in rats.
Gastroenterology, 140 (2011), pp. S57-S58
[53.]
A.D. Markland, P.S. Goode, O.S. Palsson, K.L. Burgio, J.B. Whitehead, W.E. Whitehead.
Association of low dietary intake of fiber and liquids with constipation: evidence from the national health and examination survey (NHANES).
Gastroenterology, 140 (2011), pp. S152
[54.]
J.Y. Chang, G.R. Locke, C.D. Schleck, A.R. Zinsmeister, N.J. Talley.
Familial aggregation of chronic constipation in olmsted county, minnesota: a population based study.
Gastroenterology, 140 (2011), pp. S525
[55.]
N.A. Koloski, M. Jones, R.S. Gill, P.M. Forder, N.J. Talley.
Long term risk factors for the development of constipation in older community dwelling women.
Gastroenterology, 140 (2011), pp. S359-S360
[56.]
E. Rey, M.J. Jimenez-Cebrian, M. Barceló, A. Lopez-Rocha.
The prevalence of fecal impaction in nursing homes: a pilot study.
Gastroenterology, 140 (2011), pp. S55
[57.]
A. Lembo, H. Schneier, B.J. Lavins, et al.
The effect of linaclotide on measures of abdominal and bowel symptoms in patients with chronic constipation and abdominal pain: pooled results from two phase 3 trials.
Gastroenterology, 140 (2011), pp. S49
[58.]
A.V. Emmanuel, R. Kerstens, L.M. Vandeplassche.
Prucalopride improves bowel function and colonic transit time in patients with constipation.
Gastroenterology, 140 (2011), pp. S612
[59.]
J.F. Tack, R. Kerstens, L.M. Vandeplassche.
Efficacy and safety of oral prucalopride in female patients with chronic constipation: pooled data of 3 pivotal trials.
Gastroenterology, 140 (2011), pp. S614-S615
[60.]
M. Camilleri, P. Robinson, R. Kerstens, L.M. Vandeplassche.
Safety and adverse event profiles of oral prucalopride are similar in elderly and adult patients with chronic constipation.
Gastroenterology, 140 (2011), pp. S606-S607
[61.]
W.D. Chey, M. Camilleri, L. Chang, L. Rikner, H. Graffner.
A3309, an ileal bile acid transport (IBAT /ASBT) inhibitor, significantly improved stool frequency and other constipation-related complaints in adults with chronic constipation: data from an 8-week, randomized, double-blind, placebo-controlled study.
Gastroenterology, 140 (2011), pp. S3
[62.]
J.E. Pandolfino, S.K. Ghosh, J. Rice.
Classifying esophageal motility by pressure topography characteristics: a study of 400 patients and 75 controls.
Am J Gastroenterol, 103 (2008), pp. 27-37
[63.]
R. Sweis, A. Anggiansah, R. Anggiansah, J. Fong, T. Wong, M.R. Fox.
Inclusion of Solid swallows and a test meal increase the diagnostic yield of high resolution manometry (HRM) in patients with dysphagia.
Gastroenterology, 140 (2011), pp. S77
[64.]
J.E. Pandolfino, M.A. Kwiatek, T. Nealis, W. Bulsiewicz, J. Post, P.J. Kahrilas.
Achalasia: a new clinically relevant classification by high-resolution manometry.
Gastroenterology, 135 (2008), pp. 1526-1533
[65.]
A. Anumandla, D.M. Bethards, A. Ouyang.
Does the Chicago Classification alter the management of patients with suspected esophageal motor disorders?.
Gastroenterology, 140 (2011), pp. S297-S298
[66.]
J. Zhao, M. Fox, Y. Cong, et al.
Lactose intolerance in patients with chronic functional diarrhoea: the role of small intestinal bacterial overgrowth.
Aliment Pharmacol Ther, 31 (2010), pp. 892-900
[67.]
J. Yang, M.R. Fox, Y. Cong, et al.
Lactose intolerance in patients with diarrhea predominant irritable bowel syndrome is associated with mucosal immune activation and anxiety.
Gastroenterology, 140 (2011), pp. S110-S111
[68.]
S.S. Rao.
Biofeedback therapy for constipation in adults.
Best Pract Res Clin Gastroenterol, 25 (2011), pp. 159-166
[69.]
N. Ozkutuk, I. Eser, S. Bor.
Effect of biofeedback therapy on patients with dyssynergic defecation disorder and quality of life.
Gastroenterology, 140 (2011), pp. S608
[70.]
J. Go, J. Valestin, C.K. Brown, et al.
Is biofeedback therapy effective in improving quality of life in dyssynergic defecation? A randomized clinical trial.
Gastroenterology, 140 (2011), pp. S52
[71.]
S.S. Rao, J. Valestin, C.K. Brown, et al.
Home or office biofeedback therapy for dyssynergic defecation-randomized controlled trial.
Gastroenterology, 140 (2011), pp. S160
[72.]
K. Blondeau, V. Boecxstaens, N. Rommel, et al.
Baclofen improves symptoms and postprandial flow events in patients with rumination and supragastric belching/aerophagia.
Gastroenterology, 140 (2011), pp. S123
[73.]
P. Woodland, R.S. Gill, J. Jafari, et al.
Objective assessment of aerophagia during meals in normal subjects and patients with post-prandial bloating and belching.
Gastroenterology, 140 (2011), pp. S704
[74.]
E. Rey, M.J. Devesa, C. Almansa, M. Barceló, M. Diaz-Rubio.
Prevalence of non cardiac chest pain and associated factors in a spanish population.
Gastroenterology, 140 (2011), pp. S230
[75.]
J.H. Allen, G.M. De Moore, R. Heddle, J.C. Twartz.
Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse.
Gut, 53 (2004), pp. 1566-1570
[76.]
D.A. Simonetto, A.S. Oxentenko, M.L. Herman, J. Szostek.
Cannabinoid hyperemesis: a case series of 98 patients.
Gastroenterology, 140 (2011), pp. S806
Copyright © 2011. Elsevier España S.L.. Todos los derechos reservados
